Differences in prognostic factors and outcome in community-acquired pneumonias (CAP) caused by viral pathogens (VP) or streptococcus pneumoniae (SP) Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001
An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by Pseudomonas aeruginosa Source: Eur Respir J 2005; 26: Suppl. 49, 187s Year: 2005
S. pneumoniae community-acquired pneumonia (SP-CAP): relationship between mortality and antibiotic susceptibility and risk factors for drug resistanceSource: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001
The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006
Antibacterial activity of telithromycin (TEL) and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 186s Year: 2004
Lower overall healthcare costs with telithromycin (TEL) versus clarithromycin (CLA) in community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 152s Year: 2003
Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009
Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in PROTEKT years 1–5 (1999–2004) Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006
Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002
Genetic diversity of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolates from community acquired pneumonia (CAP) in china Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008
Impact of telithromycin (T), azithromycin (A) and cefuroxime axetil (C) on the carriage of resistant streptococcus pneumoniae (Sp ) in pts with acute exacerbation of chronic bronchitis (AECB) Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Streptococcus pneumoniae resistance pattern and its clinical implicationsSource: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006
Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005
Impact of initial antibiotic choice on mortality from pneumococcal pneumonia Source: Eur Respir J 2006; 27: 1010-1019 Year: 2006
Early mortality in patients with community-acquired pneumonia: causes and risk factors Source: Eur Respir J 2008; 32: 733-739 Year: 2008
Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005
The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
Prevalence of relevant multi-drug resistant (MDR) pathogens in a bronchiectasis (BE) cohort. Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019
Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015